Stock Quote
Data Provided by Refinitiv. Minimum 15 minutes delayed.
We are a clinical-stage liver therapeutics company pioneering a new class of medicines designed to bring safe and efficacious fibrosis and cancer treatments to patients.
By employing our world-leading expertise in galectin and LOXL2 biology, we have developed our lead product candidates to modulate multiple disease pathways simultaneously and work synergistically with and enhance the efficacy of other therapeutics.
Our research indicates galectin-3 and LOXL2 are implicated in disease progression and may also be pivotal to new therapeutic strategies. These proteins play significant roles in inflammation, fibrosis, and the development and progression of cancer, making them promising targets for effective treatments.
Our efforts to date have already begun to show potential. For example, our small molecule galectin-3 inhibitor, GB1211, has shown preclinical promise in reversing galectin-3-induced resistance to checkpoint inhibitors. We anticipate that our concentrated efforts will lead to new advancements in the management of HCC, BTC, liver fibrosis, and cirrhosis, providing patients with more options and better outcomes. We announced topline results from our Phase 1b/2a GULLIVER-2 study which showed statistically significant reductions in liver enzymes and other positive biomarker effects after up to 12 weeks of treatment in [42] patients.
Galecto’s increased focus on liver diseases is an exciting chapter in our company’s evolution. As we deepen our understanding of these diseases, we’re poised to make significant strides in the development of novel therapies. This focus underscores our commitment to transforming patients’ lives by providing innovative solutions to complex medical challenges.
Data Provided by Refinitiv. Minimum 15 minutes delayed.